Fushuang Zheng1, Hongyan Zhang1, Jibin Lu1. 1. Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for about 80-85% of lung cancers. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib are considered the best choice for first-line treatment for the patients with NSCLC harboring EGFR-activating alterations. Nonetheless, 10-30% of patients may not obtain an objective response and may also experience rapid progression. The aim of our research, based on the integrative bioinformatics review, was to identify the possible miRNAs involved in gefitinib resistance. METHOD: A gefitinib-resistant network composed of 15 miRNAs and 34 targets were constructed by using the bioinformatics analyses of three microarray datasets. Of these miRNAs, effects of miR-342-3p on gefitinib resistance were investigated on a gefitinib-resistant cell model (A549/GR and PC/GR cells). RESULTS: We reported that over-expression of miR-342-3p could significantly increase the resistance to gefitinib of A549/GR and PC9/GR cells and vice versa. Then, we recognized CPA4 as a target of hsa-miR-342-3p by a luciferase reporter assay. The increase in hsa-miR-342-3p levels led to a significant reduction in CPA4 protein expression. However, the opposite results were observed upon miR-342-3p knockdown. Finally, we found that enforced CPA4 expression partially reversed miR-342-3p effects in A549/GR cells. CONCLUSIONS: Collectively, these findings suggest that the upregulation of miR-342-3p contributes to gefitinib resistance by targeting CPA4, which may serve as a potential treatment option to overcome gefitinib resistance in patients with NSCLC. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for about 80-85% of lung cancers. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib are considered the best choice for first-line treatment for the patients with NSCLC harboring EGFR-activating alterations. Nonetheless, 10-30% of patients may not obtain an objective response and may also experience rapid progression. The aim of our research, based on the integrative bioinformatics review, was to identify the possible miRNAs involved in gefitinib resistance. METHOD: A gefitinib-resistant network composed of 15 miRNAs and 34 targets were constructed by using the bioinformatics analyses of three microarray datasets. Of these miRNAs, effects of miR-342-3p on gefitinib resistance were investigated on a gefitinib-resistant cell model (A549/GR and PC/GR cells). RESULTS: We reported that over-expression of miR-342-3p could significantly increase the resistance to gefitinib of A549/GR and PC9/GR cells and vice versa. Then, we recognized CPA4 as a target of hsa-miR-342-3p by a luciferase reporter assay. The increase in hsa-miR-342-3p levels led to a significant reduction in CPA4 protein expression. However, the opposite results were observed upon miR-342-3p knockdown. Finally, we found that enforced CPA4 expression partially reversed miR-342-3p effects in A549/GR cells. CONCLUSIONS: Collectively, these findings suggest that the upregulation of miR-342-3p contributes to gefitinib resistance by targeting CPA4, which may serve as a potential treatment option to overcome gefitinib resistance in patients with NSCLC. 2019 Journal of Thoracic Disease. All rights reserved.
Entities:
Keywords:
CPA4; Gefitinib; miR-342-3p; non-small cell lung cancer (NSCLC)
Authors: Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky Journal: Nat Genet Date: 2005-04-03 Impact factor: 38.330
Authors: K Yonesaka; K Hirotani; H Kawakami; M Takeda; H Kaneda; K Sakai; I Okamoto; K Nishio; P A Jänne; K Nakagawa Journal: Oncogene Date: 2015-05-11 Impact factor: 9.867
Authors: Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge Journal: Cell Date: 2003-12-26 Impact factor: 41.582
Authors: Jiacong Wei; Anthonie J van der Wekken; Ali Saber; Miente M Terpstra; Ed Schuuring; Wim Timens; T Jeroen N Hiltermann; Harry J M Groen; Anke van den Berg; Klaas Kok Journal: Cancers (Basel) Date: 2018-01-04 Impact factor: 6.639
Authors: Florian Janke; Farastuk Bozorgmehr; Sabine Wrenger; Steffen Dietz; Claus P Heussel; Gudula Heussel; Carlos F Silva; Stephan Rheinheimer; Manuel Feisst; Michael Thomas; Heiko Golpon; Andreas Günther; Holger Sültmann; Thomas Muley; Sabina Janciauskiene; Michael Meister; Marc A Schneider Journal: Cancers (Basel) Date: 2020-04-12 Impact factor: 6.639